PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...
PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...
Octapharma USA is offering Balfaxar (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex). The new non-activated four factor prothrombin complex concentrate (4F-PCC) ...
PARAMUS, N.J., Jan. 3, 2024 /PRNewswire/ -- Octapharma USA has announced Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) is now available. The new ...
For patients who experience excessive bleeding during cardiac surgery, four-factor prothrombin complex concentrate (4F-PCC), a blood product that contains clotting factors, is significantly more ...
Patient and Healthcare Personnel Safety Go Hand in Hand Keeping nurses safe as healthcare changes is imperative to keeping patients safe. The goals are inseparable. Medscape Nurses, November 25, 2013 ...
PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback